TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Non-invasive Ventilation in Hypercapnic COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with previously diagnosed severe COPD (FEV1 \<50% predicted) and daytime hypercapnia (PaCO2 or TcCO2 \> 45 mmHg)~Exclusion Criteria:~* Lung disease besides COPD (e.g., pulmonary fibrosis, bronchiectasis, pulmonary arterial hypertension) other than well controlled asthma~* Unrevascularized coronary artery disease, angina, prior heart attack or stroke, congestive heart failure~* Uncontrolled hypertension (SBP \>160, DBP \>95)~* Unwilling or unable to withhold CPAP during polysomnography~* Presence of tracheostomy~* Hospitalization within the past 90 days~* Prior peptic ulcer disease, esophageal varicies, or gastrointestinal bleeding (\< 5 years)~* Prior gastric bypass surgery~* Anticoagulant use (other than aspirin) or bleeding diathesis (only for esophageal catheter placement)~* Chronic liver disease or end-stage kidney disease~* Allergy to any of the study medications~* Regular use of medications known to affect control of breathing (opioids, benzodiazepines, theophylline)~* Insomnia or circadian rhythm disorder~* Active illicit substance use or \>3 oz nightly alcohol use~* Psychiatric disease, other than controlled depression~* Pregnancy~* Prisoners~* Cognitive impairment, unable to provide consent, or unable to carry out research procedures

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Non-invasive ventilation (Type: EXPERIMENTAL): Subjects will undergo a baseline night with standard polysomnography, followed by a treatment night using non-invasive ventilation under polysomnography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (\> 18 years of age) patients with documented HCC tumor mass \>3cm, who are scheduled to undergo TACE with additional selective internal radiation therapy (SIRT)~* The appropriate criteria for inclusion for this patient population are:~* Biopsy or radiological diagnosis of HCC (defined as Organ Procurement and Transplantation Network (OPTN\*) Category 5 lesion either on CT or MRI)~* Scheduled for TACE (using doxorubicin-eluting beads) + SBRT~* Willingness to undergo PET/CT~* Able to lie on the imaging table for up to 1 hour.~* Able to provide signed informed consent.~* Women with childbearing potential must have a negative urine Beta-Human Chorionic Gonadotropin (β-hCG) test day of procedure~Exclusion Criteria:~* Estimated life expectancy \<12 months or serious medical co-morbidities that would preclude definitive local therapy~* Unable to lie on the imaging table~* Age less than 18 years.~* Pregnancy or lactation~* Inability or unwillingness to provide informed consent.~* Weight \>500 lbs (the weight limit of the tomograph gantry table)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMISO PET imaging post TACE and Stereotactic body radiation therapy (SBRT) (Type: EXPERIMENTAL): FMISO imaging at baseline, post-TACE and post-SBRT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive eligible patients aged 18 to 70~* Diagnosis of unipolar major depression using DSM-IV criteria with moderate to severe symptoms (score e 18 on the Hamilton Depression Rating Scale-HDRS- of 17 items).~* There was a wash-out of 1 week of any antidepressant drug (specifically 28 days for fluoxetine) prior entering the study.~* Written informed consent was obtained from all participants.~Exclusion Criteria:~* Concurrent psychiatric disorders (DSM IV axis I, II cluster A or B)~* Failure to respond to drug treatment in current depressive episode~* Previous resistance to SSRIs or other antidepressant drug~* Suicide risk score e 3 on the HDRS.~* Participation in other drug trials within the previous month~* Presence of delusions or hallucinations~* History of substance abuse (including alcohol) in the past three months~* Pregnancy or lactation~* Organic brain disease or history of seizures~* Serious organic illnesses such as hypo or hyperthyroidism,cardiac arrhythmias, asthma, diabetes mellitus.~* Myocardial infarction in the past 6 month~* Frequent or severe allergic reactions~* Concomitant use of other psychotropic drugs (benzodiazepines were allowed), lockers or catecholamine-depleting agents~* Current structured psychotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine plus placebo (Type: PLACEBO_COMPARATOR): None
- Fluoxetine plus DU125530 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Correlation Between Changes in Measures of the Visual System and Changes in Concussion-associated Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants must be 16 years or older~* Diagnosis of concussion by a medical doctor~* Participants must have concussion-related symptoms lasting at least 8 days, and no more than 70 days at the time of recruitment.~Exclusion Criteria:~* Participants with strabismus or a history of treated strabismus~* Head trauma other than a concussion (minor head injury)~* History of migraine or known neurologic disorders

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rates of Recovery From Strenuous Exercise in Physically Active Older Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Sedentary (exercise \< 1 time/week) or well-trained individuals (exercise ≧ 2 times/week)~* Ages 18-39 and 50-80 years~* Individuals who can safely exercise~Exclusion Criteria:~* Individuals who reports Symptoms or Signs Suggestive of Disease on the Health Research Questionnaire (heart and respiratory problems, dizziness and ankle edema).~* Individuals who report substance abuse within the last 6 months (elicit drugs, alcohol)~* Smokers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Young Fit (Type: EXPERIMENTAL): Young (18-39 yrs) people who have endurance training habit
- Young Unfit (Type: EXPERIMENTAL): Young (18-39 yrs) people who have sedentary lifestyle.
- Older Fit (Type: EXPERIMENTAL): Older (50-80 yrs) people who have endurance training habit
- Older Unfit (Type: EXPERIMENTAL): Older (50-80 yrs) people who have sedentary lifestyle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1 Locally Advanced stage Cervical Cancer 2. Zubrod performance status 0-2 3. Negative urine or serum pregnancy test for women of child-bearing potential 4. Agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment 5. Not a candidate for intracavitary brachytherapy~Exclusion Criteria:~1. Pregnancy~2. Concurrent untreated cancer excluding non-Melanoma skin cancer~3. Previous pelvic radiation~4. Active Inflammatory Bowel disease, Collagen vascular disease - systemic lupus erythematosus (SLE), scleroderma~5. Age \<18~6. Unable to consent for study~7. Severely immunocompromised patients ( such as Transplant , on immunosuppressive drugs)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- SABR Boost Therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Reducing Stomach Acid on Post-tonsillectomy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All healthy children ages 5-18 years scheduled for tonsillectomy and /or adenotonsillectomy for sleep disturbance secondary to airway obstruction at Children's Hospital Boston~Exclusion Criteria:~* Patients on any medications other than the study drug (Lansoprazole or placebo), Amoxicillin®, and acetaminophen with or without codeine~* An underlying medical condition which would necessitate an alteration in the anesthetic regimen~* Patients allergic to any of the medications in the protocol~* History of chronic tonsillitis~* History of chronic pain conditions~* History of active gastro-esophageal reflux disease~* Surgery in addition to tonsillectomy/adenotonsillectomy (except for myringotomy)~* Cognitive/developmental disorders~* Inability to use a self-report pain scale

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Post-operative administration of Lansoprazole
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment~* Able to comply with the study protocol~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with HER2-positive unresectable LA/mBC (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age ≥ 18 years~* Histological or cytological evidence of lung cancer~* Presence of bone metastases documented on bone X-ray, bone ECT, CT scan or MRI scan~* Mean pain score ≥ 4 during 3-day baseline period on the WORSE pain scale of the VAS~* Patients must be on a stable dose of analgesics over the 3-day baseline period (maximum 15% variation is allowed)~* ECOG Performance status of 0-3 (patients with PS of 3 must have their score based on bone pain, not underlying neoplastic disease)~* Adequate renal function: creatinine clearance ≥ 50 ml/min (cockroft formula) and serum creatinine ≤ 2.0mg/dl (168 µmol/L); ALT or AST within 2 times the upper limit of the normal range~Exclusion Criteria:~* Patients with an uncontrolled infection~* Hypocalcemia~* Patients who have received a bisphosphonate within 3 weeks of the start of the Baseline period or who are currently receiving another bisphosphonate~* Patients with known hypersensitivity to any of the components of ibandronic acid~* Patients who are pregnant or lactating~* Radiotherapy to bone within the 28 days prior inclusion or during the trial duration~* Patient who are currently treated with any other investigational therapy or have received it within 30 days of the first schedule day of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Intravenous infusion of either 6mg Bondronat on three consecutive days
- B (Type: ACTIVE_COMPARATOR): Intravenous infusion of 6mg Bondronat on one day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing pre-operative pelvic chemo-radiotherapy for histologically confirmed rectal adenocarcinoma, with the following staging: cT3N0-2, cT4N0-2, cT(any)N1-2, cT(any)N(any) CRM at-risk \[AJCC version V\]~* Staging / imaging of pelvis with MRI, and CT Thorax/Abdomen~* No evidence of metastatic disease~* ECOG Performance Status 0 - 2~* Age \> or equal to 18 years~* Provision of written informed consent in line with ICH-GCP guidelines~Exclusion Criteria:~* Previous radiotherapy to the pelvic region~* Patients in whom induction chemotherapy has been delivered prior to chemo- radiotherapy~* History of inflammatory bowel disease~* Previous hip replacement~* Previous bowel surgery (excluding procedures/operations which would not result in small bowel adhesions - at the discretion of the Principal Investigator)~* Patients with other syndromes/conditions associated with increased radiosensitivity~* Any other co-existing malignancies within the past 5 years other than non- melanoma skin cancer~* Pregnancy or lactation at the time of proposed randomisation~* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study or if it is felt by the research / medical team that the patient may not be able to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): 50.4 Gy / 28# external beam pelvic radiotherapy delivered using IMRT
- Control Arm (Type: NO_INTERVENTION): 50.4 Gy / 28# external beam pelvic radiotherapy delivered using a 3-Dimensional (3-D) planned technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with HER2+ stage IV breast cancer that have been maximally treated and not in a complete remission~* Patients must have measurable disease per imaging studies performed within 60 days of enrollment as described below:~  * Extra skeletal disease that can be measured with conventional or spiral computed tomography (CT) techniques~ * Skeletal or bone-only disease that is measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) or magnetic resonance imaging (MRI)~* Patients can be receiving trastuzumab and/or lapatinib and/or hormonal therapy and/or bisphosphonate therapy~* HER2 overexpression in the primary tumor or metastasis by immunohistochemistry (IHC) of 3+, or documented gene amplification by fluorescent in situ hybridization (FISH) analysis~* Patients must be human leukocyte antigen (HLA)-A2 positive~* Eastern Cooperative Oncology Group (ECOG)/Zubrod scale of =\< 1~* Patients must be off immunosuppressive treatments (i.e., chemotherapy or systemic steroids) 3 weeks prior to first vaccine~* Patients on trastuzumab must have a baseline left ventricular ejection fraction (LVEF) measured by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) \>= the lower limit of normal for the facility within 3 months of enrollment to study~* Subjects of reproductive ability must agree to use contraceptives during the entire study period~Exclusion Criteria:~* White blood cell (WBC) \< 3000/mm\^3~* Hemoglobin (Hgb) \< 10 mg/dl~* Platelets \< 100,000/mm\^3~* Serum creatinine \> 2.0 mg/dl~* Serum bilirubin \> 1.5 x upper limit of normal~* Any contraindication to receiving sargramostim (GM-CSF) based vaccine products~* Concurrent enrollment in other treatment studies~* New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, or unstable angina~* Pregnant or breast-feeding women~* History of disorders associated with immunosuppression such as human immunodeficiency virus (HIV)~* Active brain metastasis

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (HER-2/neu peptide vaccine) (Type: EXPERIMENTAL): Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biologic high risk Multiple Myeloma:~  * Stage II/III Multiple Myeloma, any of: t(4; 14), t(14; 16),(14:20) by Fish; 17P- by conventional cytogenetics or Fish; ∆13 by conventional cytogenetics; Hypodiploidy by conventional cytogenetics.~    * Relapsed or persistent multiple myeloma after ASCT.~   * Persistent multiple myeloma, regardless of previous therapies.~   * Plasma cell leukemia, regardless of previous therapies.~* Age up to 70 years old (less than 71 years old at the date of transplant admission).~* Disease status: in CR, nCR, VGPR, PR or stable disease within 1 month of admission~* Patients with non-secretory and oligosecretory disease are eligible if they meet certain criteria within 2 weeks prior to the transplant.~* Specific renal, liver, cardiac, and pulmonary function requirements(all must be met within 30 days of transplant admission)~Exclusion Criteria:~* Persistent invasive infections, not controlled by antimicrobials.~* HIV-1/HIV-2 or HTLV-1/HTLV-2 seropositivity.~* Uncontrolled medical or psychiatric disorder.~* No response or progressive disease at the time of transplantation.~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Flu-Bu4 (Type: EXPERIMENTAL): Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old, both men and women~* Existing implantable cardioverter-defibrillator (ICD)~* Referred for implantation of a continuous flow LVAD~Exclusion Criteria:~* Permanent left ventricular epicardial defibrillator in place~* Congenital heart disease with single ventricle physiology~* Right ventricular assist device (RVAD) in place~* Existing pacing indication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Native Conduction (Type: PLACEBO_COMPARATOR): Devices will be programmed to continuous atrial pacing at an AAI (atrial inhibited pacing) setting with base rate 90 bpm. Patients will not receive ventricular pacing.
- Continuous RV Pacing (Type: EXPERIMENTAL): Devices will be programmed to continuous dual chamber pacing at a DDD (dual chamber dual pacing) setting with base rate ≥ 90 bpm (not to exceed 100 bpm) to achieve a majority (\>80%) of paced right ventricular beats

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues